Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aridis Pharmaceuticals Inc

ARDS
Current price
0.087 USD +0.0053 USD (+6.49%)
Last closed 0.081 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 570 377 USD
Yield for 12 month -90.84 %
Week
Month
Year
ARDS
21.11.2021 - 28.11.2021

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California. Address: 983 University Avenue, Los Gatos, CA, United States, 95032

Analytics

WallStreet Target Price

2 USD

P/E ratio

Dividend Yield

Current Year

Last Year

+1 535 000 USD

Current Quarter

+417 000 USD

Last Quarter

+19 647 000 USD

Current Year

Last Year

+1 535 000 USD

Current Quarter

+417 000 USD

Last Quarter

+19 647 000 USD

Key Figures ARDS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -347 000 USD
Operating Margin TTM -208.39 %
PE Ratio
Return On Assets TTM -4.4 %
PEG Ratio
Return On Equity TTM
Wall Street Target Price 2 USD
Revenue TTM 22 359 000 USD
Book Value -0.27 USD
Revenue Per Share TTM 0.7 USD
Dividend Share
Quarterly Revenue Growth YOY 4.5 %
Dividend Yield
Gross Profit TTM -22 605 000 USD
Earnings Share -0.16 USD
Diluted Eps TTM -0.16 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -5.11 %

Dividend Analytics ARDS

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ARDS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ARDS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 2.0606
Enterprise Value Revenue 17.5708
Price Sales TTM 7.3343
Enterprise Value EBITDA -1.2481
Price Book MRQ 5.3976

Financials ARDS

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ARDS

For 52 weeks

0.05 USD 1.75 USD
50 Day MA 0.083 USD
Shares Short Prior Month 1 848 149
200 Day MA 0.22 USD
Short Ratio 0.22
Shares Short 2 003 965
Short Percent 6.8 %